The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
